Results 21 to 30 of about 120,528 (253)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS

Jurnal Urologi Indonesia, 2016
Objective: In Hasan Sadikin General Hospital Bandung prostate biopsy is recommended for patients with prostate specific antigen (PSA) levels above 10 ng/mL or PSA density (PSAD) above 0.15 if PSA in between 4–10 ng/mL.
Daniel Simanjuntak, Ferry Safriadi
doaj   +1 more source

Evaluation of Phage Display Discovered Peptides as Ligands for Prostate-Specific Membrane Antigen (PSMA) [PDF]

, 2013
The aim of this study was to identify potential ligands of PSMA suitable for further development as novel PSMA-targeted peptides using phage display technology. The human PSMA protein was immobilized as a target followed by incubation with a 15-mer phage
Shen, Duanwen, Shen Duanwen, Fei Xie (437662), Xie, Fei, Edwards W. Barry, W. Barry Edwards (437663), Shen, D, Duanwen Shen, W. Barry Edwards, Xie Fei, W Barry Edwards, Fei Xie, Edwards, WB, Duanwen Shen (437661), Xie, F, Edwards, W. Barry   +15 more
core   +1 more source

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience

, 2023
Objective: Lutetium-177 prostate-specific membrane antigen-617 is a novel alternative therapeutic option in metastatic castration-resistant prostate cancer, especially useful for patients who do not respond to standard therapy methods.
Maman, Adem, Adem Maman
core   +1 more source

Prevention and early detection of prostate cancer. [PDF]

, 2014
Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer.
Culig, Zoran, Vecchia, Carlo La, Stenzl, Arnulf, P. H. Brown, Meyskens, FL, H. Schmid, Thorat, M.A., Parnes, Howard L., Key, Timothy, Wilt, Timothy J, Rittenhouse, H., Minasian, Lori M, Perner, S. (Sven), Schmid, H-P, Cuzick, J, Minasian, LM, Brawley, Otis W., Ford, Leslie G., G. Andriole, Perner, S, Key, Timothy J., D. Ilic, Ilic, Dragan, Parker, C. (C.), Key, TJ, Andriole, Gerald, Hamdy, Freddie C., R. A. Eeles, Holmberg, Lars, J. Schalken, Eeles, R. (Rosalind), Parker, C, Lilja, Hans, Wolk, Alicja, Holmberg, Lars,, Parnes, Howard L, Tombal, B, T. J. Wilt, Schmitz-Dräger, Bernd J., Schmitz-Draeger, BJ, F. H. Schröder, Hamdy, Freddie C, F. C. Hamdy, Lilja, H, Marberger, Michael, Lund University., Hamdy, FC, Schalken, J, Andriole, G.L. (Gerald), Andriole, G, Cuzick, Jack, Hamdy, F. (Freddie), Schmid, HP, Vecchia, C. La, Schmid, Hans Peter, Ford, L.G., A. Wolk, Tombal, Bertrand, Schmid, H.P., Meyskens, F.L. (Frank L), Schmitz-Dräger, BJ, Wilt, TJ, Schmid, H.-P. (Hans-Peter), Thorat, Mangesh A, Brawley, O.W., T. J. Key, Lilja, H., Schalken, J.A. (Jack), Parker, C., Holmberg, L, Schmitz-Dräger, Bernd J, M. Marberger, La Vecchia, C, Key, T.J. (Timothy J), Brawley, OW, F. L. Meyskens, Eeles, Rosalind A, Schröder, F.H. (Fritz), B. J. Schmitz Dräger, Brown, PH, Parker, Chris, Ilic, D, Ilic, D. (Dragan), Ford, L.G. (Leslie G), C.La Vecchia, Wolk, K. (Kerstin), Tombal, B. (Bertrand), Schmitz-Drager, B.J., Minasian, L.M. (Lori M), L. M. Minasian, Schröder, Fritz H, H. Lilja, B. Tombal, Schalken, J.A., Brown, Powel H, Rittenhouse, H. (Harry), O. W. Brawley, Stenzl, A, C. Parker, Brawley, O.W. (Otis W), Meyskens, Frank L., Vecchia, C.L. (Carlo La), Culig, Z., Brown, P.H., Parnes, HL, Cuzick, J., Wilt, Timothy J., Ford, Leslie G, Z. Culig, Culig, Z. (Zoran), L. G. Ford, Brawley, Otis W, Key, Timothy J, Schmitz-Dräger, B.J. (Bernd J), S. Perner, Marberger, M, Schalken, Jack, Thorat, M.A. (Mangesh A), Hamdy, F.C., Stenzl, A. (Arnulf), Wilt, T.J., Wolk, A, Schroder, F.H., Culig, Z, Key, T.J., Eeles, R.A., Lilja, Hans,, Ford, LG, Lilja, H. (Hans), Parnes, H.L. (Howard L), Eeles, RA, Marberger, M., Andriole, G., Schröder, Fritz H., Schmid, Hans-Peter, Schröder, FH, Stenzl, A., L. Holmberg, Meyskens, F.L., Thorat, Mangesh A., A. Stenzl, Meyskens, Frank L, Brown, P.H. (Powel H), J. Cuzick, La Vecchia, Carlo, H. Rittenhouse, H. L. Parnes, Wolk, A., Rittenhouse, Harry, Perner, Sven, M. A. Thorat, Tombal, B., Schröder, Fritz, Minasian, Lori M., Ilic, D., Minasian, L.M., Parnes, H.L., Rittenhouse, H, Marberger, M. (Michael), Perner, S., Holmberg, L. (Lars), Cuzick, J. (Jack), Wilt, T.J. (Timothy J.), Holmberg, L., Thorat, MA, Eeles, Rosalind A., Brown, Powel H.   +166 more
core   +1 more source

Prostate Specific Antigen [PDF]

American Journal of Clinical Pathology, 2006
Prostate cancer is a highly prevalent disease that is characterized by a wide range of aggressiveness, ranging from the clinically irrelevant to the rapidly progressive, lethally metastatic. Since its introduction as a serum test in the late 1980s, prostate-specific antigen (PSA) has been increasingly promulgated as an important biomarker for prostate ...
Kristin R. Swanson, Hana L.P. Harpold, Lawrence D. True   +2 more
  +5 more sources

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer

Prostate International, 2013
Racial differences exist in the incidence of prostate cancer (PCa). Although many studies have looked at the performance of prostate-specific antigen (PSA) and PSA density (PSAD) in the detection of PCa, only a few have looked at it in relation to ...
Ahmad Anies Shahab, Doddy M. Soebadi, Wahjoe Djatisoesanto, Sunaryo Hardjowijoto, Soetojo Soetojo, Lukman Hakim   +5 more
doaj   +1 more source

Complexed Prostate-specific Antigen and the “Prostate-specific Antigen Gap” [PDF]

Clinical Chemistry, 1999
Jung et al. (1) reported an apparent gap between total serum prostate-specific antigen (t-PSA) and the sum of free PSA (f-PSA) plus α1-antichymotrypsin-PSA (ACT-PSA) in patients with prostate carcinoma (PCa) but not in those with benign prostatic hypertrophy (BPH).
Iain S Ross, Nicholas P Cohen, Patrica A Duff, Arthur Dickie, Ian Mitchell, Bernard L Croal   +5 more
openaire   +1 more source

The Percentage of [-2]Pro-Prostate-Specific Antigen and the Prostate Health Index Outperform Prostate-Specific Antigen and the Percentage of Free Prostate-Specific Antigen in the Detection of Clinically Significant Prostate Cancer and Can Be Used as Reflex Tests [PDF]

, 2022
Context.— There is a need to avoid the overdiagnosis of prostate cancer (PCa) and to find more specific biomarkers. Objective.— To evaluate the clinical utility of [−2]pro–prostate-specific antigen ([−2]proPSA) derivatives in detecting clinically ...
Marta, JC, Bernardino, RM, Holdenrieder, S, Ribeiro, R, Pinheiro, LC, Guerra, J, Garrido, MM, Fernandes, F, Guimarães, JT, Pereira, MH   +9 more
core   +1 more source

Transcriptional regulation of prostate kallikrein-like genes by androgen. [PDF]

, 1992
Using gene-specific synthetic oligonucleotides the expression and regulation of kallikrein-like genes in the human prostatic cancer cell line LNCaP were studied.
Schulz, Peter, Fittler, Friedrich, Wolf, Dieter A.   +2 more
core   +1 more source

PROSTATE-SPECIFIC ANTIGEN VELOCITY AND REPEATED MEASURES OF PROSTATE-SPECIFIC ANTIGEN

Urologic Clinics of North America, 1997
Numerous studies evaluating different populations have shown similar findings with respect to repeated PSA measurements and PSAV. First, there is substantial within-individual variability between repeated PSA measures. Second, this variability between PSA measurements precludes the use of a simple change in PSA as a marker for prostate cancer.
H B, Carter, J D, Pearson
openaire   +2 more sources